足癬、股癬和體癬的發(fā)病率較高,又極易復(fù)發(fā),嚴(yán)重影響到患者的生活質(zhì)量。2013年11月,美國FDA批準(zhǔn)1%盧立康唑乳膏上市,外用治療趾間足癬、股癬和體癬。該藥是一種新型咪唑類外用抗真菌藥,具有抗菌譜廣、抑菌作用強的特點。研究顯示1%盧立康唑乳膏外用治療足癬、股癬和體癬安全有效,尤其是治療股癬和體癬時,僅需每日1次,治療1周,與目前其他治療藥物(需要治療2周)相比,療程更短。

The tinea pedis, tinea cruris, and tinea corporis can seriously affect the quality of life of patients due to high incidences and high recurrence rate. Luliconazole cream 1% was approved by the United States Food and Drug Administration (FDA) for the topical treatment of tinea pedis, tinea cruris and tinea corporis for external use in November 2013. Luliconazole is a novel broad-spectrum topical imidazole antifungal agent with potent antifungal effect. The studies have shown that luliconazole cream 1% is safe and effective in the treatment of tinea pedis, tinea cruris, and tinea corporis, especially for the two latter. The course of the treatment with luliconazole, once-daily for one week, is shorter than other existing drugs (usually for two weeks of treatment). This article reviews the pharmacodynamic studies and clinical evaluation for the treatment of fungal infections of luliconazole cream 1% and its development.